Item 8.01 Other Events.
On January 30, 2020, BioCorRx Inc. (the "Company") announced that the National
Institute on Drug Abuse ("NIDA"), part of the National Institutes of Health, has
confirmed the Company has been awarded a second year of funding to support the
development of a 3-month implantable depot pellet of naltrexone for the
treatment of Opioid Use Disorder. The Company refers to this treatment as
BICX102. The amount awarded, $2,831,838, remains unchanged from the previously
announced Notice of Award issued to the Company in January 2019.
On January 30, 2020, the Company issued a press release announcing the events
described in this Item 8.01. A copy of the press release is filed as Exhibit
99.1 hereto and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number Description
99.1 Press Release dated January 30, 2020
2
© Edgar Online, source Glimpses
